Introduction
Bacterial infections are the single most common cause of infection-related mortality, accounting for 36% of such deaths after allogeneic hematopoietic cell transplant (HCT). 1 The risk of bacterial infection is largely mediated by neutropenia, defined as an ANC o500 cells/ml in blood. 2, 3 Approximately 20% of neutropenic cancer patients will develop an episode of bacteremia, and delayed initiation of antibiotics until an infection is documented by culture may result in excess mortality in these patients. 4 Accordingly, antibiotic prophylaxis and empirical therapy are often used as bacterial infection risk-reduction strategies. Antibiotic prophylaxis commences at the onset of neutropenia and continues until engraftment. 5 Although this approach may prevent some bacterial infections, leading to reduced mortality, 6 ,7 the disadvantages of prophylaxis include increased antibiotic exposure with resulting higher drug costs, toxicity and the potential for development of antibiotic resistance in bacteria. Empirical antibiotic therapy is initiated at the onset of fever in neutropenic patients. The advantage of this approach is decreased antibiotic exposure compared with the prophylaxis strategy, whereas disadvantages include higher rates of infection, and the possibility that infections may advance to a critical stage before the onset of fever and the initiation of antibiotic treatment. In HCT recipients, a sequential strategy is most commonly adopted using antibiotic prophylaxis with the onset of neutropenia, followed by a change to a different (empirical) antibiotic with the onset of fever.
The FHCRC (Fred Hutchinson Cancer Research Center) has used antibiotic prophylaxis in allogeneic HCT recipients for the last two decades. In 2002, the FHCRC elected to shift from using ceftazidime to levofloxacin for antibacterial prophylaxis in this patient population. Ceftazidime is a third-generation cephalosporin with activity against Pseudomonas aeruginosa and other Gram-negative rod bacteria, but with a poor Gram-positive spectrum. Levofloxacin is a fluoroquinolone with enhanced Grampositive activity (including activity against Staphylococcus aureus) along with activity against Pseudomonas and other Gram-negative rod bacteria. The rationale underlying this transition was that levofloxacin has a broader spectrum of activity, requires only one daily dosing of 750 mg i.v. or orally and is significantly less expensive than 2 g of ceftazidime administered i.v. every 8 h. Oral levofloxacin has excellent bioavailability and is dramatically less expensive than i.v. ceftazidime for those patients who can tolerate oral medications.
The initiation of this change was associated with a mandate to monitor the outcome of this policy. In particular, we sought to determine whether levofloxacin use was associated with an increased risk of Gram-negative rod bacteremia due to quinolone-resistant bacteria, a shift in the spectrum of bacterial pathogens causing disease and an increased incidence of Clostridium difficile colitis as quinolone use is a risk factor for this infection. 8 We conducted a retrospective analysis of two consecutive treatment cohorts to compare the following outcomes during the first 100 days after transplantation: fever, failure of prophylaxis (that is, change of antibiotic), number and types of documented bacterial infections (including bacteremias), emergence of antibiotic resistance, use of antibiotic and antifungal medications and their costs. Entry into and days spent in the intensive care unit (ICU) were assessed as surrogate markers for sepsis. Relapse and mortality in the 3 years after transplantation were also described.
Patients and methods

Data collection
The study population consisted of consecutively admitted adult recipients of myeloablative allogeneic HCT at the SCCA (Seattle Cancer Care Alliance) from July 2000 to December 2004, with in-patient visits at the University of Washington Medical Center and outpatient follow-up at the SCCA clinic. Patients received either ceftazidime or levofloxacin as prophylaxis during neutropenia. Pediatric patients were excluded. Ceftazidime was the standard antibacterial prophylaxis during the study period from 2000 to 2002. After August 2002, levofloxacin prophylaxis became the standard practice. Data were collected from pharmacy charts for antibacterial and antifungal medications, and from electronic medical records for fever, ANC, bacterial culture and antibiotic resistance information.
Definitions
The underlying disease was classified as advanced for all patients not in remission, for those with acute nonlymphoblastic leukemia in second or later remission and for those with acute lymphoblastic leukemia in third remission or later. Patients with chronic myeloid leukemia were classified as having advanced disease when in blast crisis at the time of transplantation. All other patients were classified as not having advanced disease.
Infections were documented following the standard practices at the FHCRC/SCCA. In this study, fever was defined as an oral temperature of X38.3 1C. Blood cultures were obtained from patients with temperatures 438.0 1C, using two sets of culture bottles (aerobic, anaerobic, mycobacterial/fungal ¼ 1 set) obtained with initial fever and then daily sets obtained with ongoing fever. Blood cultures were also obtained with hemodynamic instability, chills and at least weekly when receiving steroids X0.5 mg/ kg as this may mask a fever. Urine cultures were obtained with fever or urinary complaints. C. difficile ELISA for common Ag and Toxin A was sent for analysis for diarrhea or fever and abdominal pain. Bronchoscopy with bronchoalveolar lavage was obtained in patients with pulmonary infiltrates or nodules seen on radiographic images.
Bacteremic episodes were defined by any positive blood culture and summarized over two overlapping time periods: first, during the initial period of neutropenia, and second, anytime during the first 100 days after transplantation. The beginning of the neutropenic period was defined by the first day after conditioning when the ANC value decreased below 500, and ended with the first day when the value exceeded 500. In patients with an initial neutropenic period that ended on transplant day þ 1 or before, infections during the second neutropenic period related to transplantation were described instead. Within each time period, additional positive cultures for the same organism recovered within 7 days of previous positive culture were considered part of the original episode, whereas positive cultures for different organisms on different days were considered separate episodes. A polymicrobial episode was defined by positive cultures for two or more organisms on the same day. Analysis of bacteremic episodes was also conducted excluding coagulase-negative staphylococci, which were the most common isolates in our HCT recipients but have low pathogenic potential.
Infections identified through other sources during the first 100 days post transplant were also summarized. Bacteriuria was defined as at least 1 þ growth of a pure culture; pyuria is not considered a reliable indicator of urinary tract infection in neutropenic patients and mixed bacteria on culture are associated with contamination during collection. Wound infection was microbiologically documented through the biopsy of s.c. tissue and excluded normal flora from non-sterile sites. Respiratory tract infection was diagnosed through sputum, bronchoalveolar lavage fluid, tracheal aspirate and/or lung biopsy, with isolation of a credible pulmonary pathogen and excluding normal oral flora, such as viridans streptococci, coagulase negative staphylococci, stomatococcus and diphtheroids.
Failure to respond to initial prophylaxis was defined as a change in antibiotic therapy, including a discontinuation of the initial treatment and use of additional drugs. As our description includes all further antibiotic treatments within the first 100 days post transplant, 'additional therapies' may include the original prophylaxis agent.
The burden of antibiotic use was quantified by the number of 'antibiotic days' during days À5 to þ 100 relative to transplantation. An 'antibiotic day' was defined as treatment with a single antibiotic on 1 day; 1 day's treatment with two antibiotic therapies was counted as 2 antibiotic days, and so on. Thus, each patient's total antibiotic days was calculated by summing up the number of days spent on each antibiotic therapy. To estimate the monetary cost of each patient's antibiotic treatment, we considered only the price paid by the clinic to acquire the medicines and ignored the cost of infusion. On the basis of common practice in our clinics, if treatment was given before day þ 21, we assumed that the i.v. cost was applicable. If given after day þ 21, the oral usage cost was applied. Patients with incomplete data on duration for selected antibiotics were excluded from analysis of antibiotic use and cost.
Antifungal use and cost were summarized in a similar manner to antibiotics. Fluconazole is used routinely at the FHCRC/SCCA for antifungal prophylaxis in HCT. However, there is some variability in the initial antifungal prophylaxis on the basis of risk factors for mould infection. Therefore, we restricted our attention to the subgroup of patients who received fluconazole as initial prophylactic therapy and described the switch to non-fluconazole (mould active) antifungal therapy after the initial transplantation period. Patients with incomplete data on duration for selected antifungals were excluded from this analysis.
Statistical analysis
Patient characteristics were compared across cohorts using the w 2 test for categorical data and the t-test for continuous data. Cumulative incidence curves were used to estimate the probabilities of the following time-to-event outcomes: fever, change in antibiotic regimen, bacteremia, bacteriuria, wound infection, respiratory tract infection and relapse-free survival (RFS). Relapse and death in the first 100 days were treated as competing risks for all infectious disease outcomes. The statistical significance of differences in event rates was evaluated using the proportional hazards regression model. The probability of entry into the ICU was estimated using a logistic regression model. Within the subset of patients treated in the ICU, the number of days spent in the ICU was compared across cohorts using the linear regression model. Factors considered as potential confounders of the relationships between the prophylactic antibiotic and the outcomes included age, sex, donor type (related vs unrelated), receipt of TBI, and cell source (PBSCs or BM). Such factors were retained in the model if their presence influenced the coefficient of interest (use of levofloxacin vs ceftazidime) by X10%. Reported P-values are two-sided and are based on the Wald statistic. No adjustments were made for multiple comparisons.
Results
The populations in the two different antibiotic prophylaxis groups were fairly similar with respect to age, diagnosis and donor type. Table 1 describes the patient characteristics by prophylaxis regimen. Significantly more patients in the ceftazidime group received BM rather than a PBSC transplant, as compared with the levofloxacin group (P ¼ 0.02). There was a significantly higher proportion of men than of women among levofloxacin recipients compared with ceftazidime recipients (P ¼ 0.02). The distribution of conditioning regimens varied by prophylaxis regimen, but this difference did not reach statistical significance.
Patients who received levofloxacin as their first prophylaxis regimen were significantly more likely to have a fever early after initiation of the prophylactic antibiotic, as compared with patients who initially received ceftazidime (estimates at day 30 were 69.0% (95% confidence interval (CI): 62.8-75.2%) and 53.7% (95% CI: 47.1-60.4%), respectively, P ¼ 0.004 after adjustment for cell source and donor type, Figure 1) . Fevers occurred at a median of 5 days (range: 0-57 days) after initiation of the original prophylaxis regimen. Similarly, more patients receiving levofloxacin prophylaxis failed to respond to their initial prophylaxis (Po0.001). Changes in the antibiotic regimen occurred at a median of 7 days (range: 1-24 days) after the start of the original regimen. Table 2 describes the therapies that patients received after failing to respond to initial prophylaxis.
The prophylaxis groups did not differ with regard to overall antibiotic use: the median number of antibiotic treatment days per patient was 34 (range: 6-120 days) in the ceftazidime group vs median 31 (range: 3-168 days) in the levofloxacin group, on the basis of complete data obtained from 171 ceftazidime-treated patients and 197 levofloxacintreated patients. The average antibiotic acquisition costs incorporating all antibiotics used in the study period were significantly lower for levofloxacin than for ceftazidime recipients: median $618 (range: $33-3378) vs median $922 (range: $216-3158), respectively (P ¼ 0.001). Among the 172 ceftazidime recipients and the 193 levofloxacin recipients who received fluconazole antifungal prophylaxis, there was no difference between groups in the overall use of antifungals, including the use of mould active agents. Antifungal acquisition costs also did not vary by antibiotic prophylaxis cohort.
The probability of at least one case of bacteremia in the first 100 days after transplantation did not vary by group (P ¼ 0.15). However, when single-organism coagulasenegative Staphylococcus (CoNS) infections were excluded, the levofloxacin group had a significantly lower probability of bacteremia than did the ceftazidime group (P ¼ 0.02). The estimated probabilities at day 100 were 29.6% (95% CI: 23.5-35.7%) for the ceftazidime group and 19.2% (95% CI: 14.0-24.4%) for the levofloxacin group (Figure 2 ).
The spectrum of bacteria causing bacteremia was similar across groups, although the number of infections for each Gram-positive bacterium was lower in the levofloxacin cohort than in the ceftazidime cohort (Table 3 ). The five episodes of Acinetobacter bacteremia in the levofloxacin group occurred in three subjects; two patients with one episode each and one patient with three episodes. One patient had infection with antibiotic-resistant Acinetobacter in the levofloxacin cohort (Table 4) .
The incidence of bacteremia in the initial post transplant period of neutropenia did not vary by group, even when the single-organism CoNS infections were excluded. Overall, the period of neutropenia started on average at day þ 2, with a range from days 0 to 9; the median end time was day þ 17, with a range from days 2 to 37. The average duration of the initial post transplant neutropenic period was 14 days, with a range of 1-34 days. There were no dramatic differences between groups in the spectrum of bacteria causing bacteremia during neutropenia.
For sources of infection other than blood, there were no significant differences between prophylaxis groups in infection rates in the first 100 days after transplantation. There was a trend suggesting that the incidence of wound infection was lower in the levofloxacin than in the ceftazidime cohort, but this difference did not reach statistical significance (day 100 estimates 4.1% (95% CI: 1.5-6.7%) and 8.8% (95% CI: 5.0-12.6%), respectively, P ¼ 0.10). There was no difference in the probability of at least one respiratory bacterial infection episode between the cohorts (day 100 estimates 11.6% (95% CI: 7.3-15.8%) for ceftazidime and 10.0% (95% CI: 6.1-14.0%) for levofloxacin groups). The incidence of least one positive urine culture in the first 100 days after transplantation did not differ significantly between ceftazidime and levofloxacin recipients: 22.7% (95% CI: 17.1-28.3%) and 16.9% (95% CI: 11.9-21.9%), respectively. However, male and female patients had significantly different experiences of this outcome: 11 of 132 (8%) men in the levofloxacin group and 2 of 107 (2%) men in the ceftazidime group had at least one positive urine culture, whereas 26 of 87 (30%) women in the levofloxacin group and 47 of 109 (43%) women in the ceftazidime group had at least one positive urine culture. The probability of at least one positive blood sample (excluding CoNS), urine, wound or respiratory culture in the first 100 days was estimated to assess the overall burden of infections. These estimates were not significantly different between prophylaxis groups (Figure 3) . However, among patients with at least one infection of any type, patients in the ceftazidime group were significantly more likely than were those in the levofloxacin group to have had an infection in two or more sites (36% (38/107) vs 20% (17/ 87), respectively, P ¼ 0.02).
There was no significant difference in the detection rates of C. difficile either by Toxin A or common Ag in the stool specimens between the two prophylaxis cohorts during the first 100 days after transplantation. Of those subjects undergoing testing to diagnose possible C. difficile disease, C. difficile Toxin A was detected in 8.8% (95% CI: 5.0-12.6%) of subjects in the ceftazidime group and in 6.4% (95% CI: 3.2-9.6%) of subjects in the levofloxacin group; C. difficile Ag was detected in 27.8% (95% CI: 21.8-33.8%) of subjects in the ceftazidime group and in 20.1% (95% CI: 14.8-25.4%) of subjects in the levofloxacin group. Ceftazidime recipients were more likely than were levofloxacin recipients to have entered the ICU during the first 100 days after transplantation: 22 vs 13%, P ¼ 0.03. However, the incidence of ICU treatment within the first 100 days after transplantation decreased over time in the study cohort: 19% among those transplanted in 2000, 25% in 2001, 16% in 2002, 18% in 2003 and 6% in 2004 (P ¼ 0.004). Thus, the difference between prophylaxis groups may be due to advances in care in the later time period of levofloxacin use. Among those treated in the ICU, the number of days spent there did not differ between groups: median 4 (range: 1-60 days) in the ceftazidime group vs median 13 (range: 1-54 days) in the levofloxacin group, P ¼ 0.42. Moreover, the proportion of patients who died within 100 days of transplantation after treatment in the ICU did not differ between groups: 38% in the ceftazidime group vs 46% in the levofloxacin group.
The use of levofloxacin instead of ceftazidime for prophylaxis did not adversely affect RFS. At 3 years post transplant, RFS was 57.1% (95% CI: 50.5-63.7%) in the levofloxacin group and 50.4% (95% CI: 43.8-57.1%) in the ceftazidime group (Figure 4) . After adjusting for cell source and TBI exposure, the hazard ratio of RFS for the levofloxacin group relative to the ceftazidime group was 0.81 with 95% CI: 0.62-1.07, P ¼ 0.13. There were 26 deaths within 100 days of transplantation in the ceftazidime group, with 14 autopsies performed and 8 documented bacterial infections contributing to death (3 Enterococcus species, 2 S. aureus, 2 polymicrobial and 1 Myocobacterium avium complex). There were 26 deaths within 100 days of transplant in the levofloxacin group, with 6 autopsies performed and 7 bacterial infections documented as contributing to death (3 Enterococcus species including 1 vancomycin-resistant enterococcus, 1 Acinetobacter, 1 Pseudomonas, 1 polymicrobial and 1 with persistent CoNS bacteremia). 
Discussion
Several randomized, placebo-controlled trials have documented the beneficial effects of levofloxacin prophylaxis in reducing rates of fever and infection in cancer patients with neutropenia 9,10 and in reducing mortality in neutropenic patients. 11, 12 Levofloxacin has several attractive characteristics including a broad spectrum of activity against Gramnegative and Gram-positive pathogens, once daily dosing, high oral bioavailability, excellent safety profile and low cost. Some investigators have advocated caution in the adoption of levofloxacin for prophylaxis on the basis of concerns regarding the potential for emergence of antibiotic resistance and a possible increase in enteric infections, such as those caused by C. difficile. 13 Indeed, several studies have shown that fluoroquinolone use is a major risk factor for C. difficile colitis.
14, 15 Bucaneve et al. 9 reported that 10 of 13 Gram-negative rods isolated from the blood of patients receiving levofloxacin prophylaxis were resistant to levofloxacin. Furthermore, levofloxacin prophylaxis at 500 mg daily has been associated with an increased incidence of viridans group streptococcal bacteremia in autologous transplant recipients. 16 Recognizing the potential deleterious consequences from instituting levofloxacin prophylaxis, we sought to monitor the clinical and microbiological impact of a change from ceftazidime to levofloxacin for antibacterial prophylaxis in allogeneic HCT recipients receiving myeloablative conditioning.
Patients receiving 750 mg levofloxacin per day as prophylaxis had a significantly higher probability of developing a fever (69.0%) than did those receiving 2 gm ceftazidime thrice daily (53.7%), although the median time to fever was the same in febrile patients (5 days). This higher incidence of fever in the levofloxacin cohort led to a higher probability of changing antibiotics (63.5%) compared with the ceftazidime cohort (45.4%), reflecting the practice of starting a different empirical antibiotic in neutropenic patients who develop a fever on prophylaxis. Patients with febrile neutropenia were most commonly switched to ceftazidime in the levofloxacin prophylaxis group, whereas those in the ceftazidime prophylaxis group were most commonly switched to imipenem (Table 2) . Vancomycin was used at similar rates in both groups. Despite the higher incidence of fever in the levofloxacin group, the use of mould-active antifungal medications was similar between groups. Thus, the lower cost of levofloxacin prophylaxis and that of ceftazidime as initial secondary therapy over imipenem contributed to the markedly lower total antibiotic cost that we documented in this analysis.
Ceftazidime prophylaxis resulted in a reduced rate of febrile episodes post HCT as compared with levofloxacin prophylaxis. Interestingly, documented bacteremia (excluding CoNS that is not susceptible to levofloxacin or ceftazidime) was less frequent among patients receiving levofloxacin prophylaxis. In addition, rates of bacteriuria, wound infection, isolation of a bacterial pathogen from respiratory culture and C. difficile Ag or toxin detection in stool specimens were consistently lower in the levofloxacin group, although not statistically significantly different. C. difficile toxin detection in stool provides evidence of toxigenic bacteria, whereas the Ag may be detected with either toxigenic or non-toxigenic strains of C. difficile. Antibiotic susceptibility profiles were monitored for each bacterial isolate and there was no trend toward isolation of more resistant bacteria in the levofloxacin cohort. Three patients in the levofloxacin prophylaxis group had Acinetobacter bacteremia, an infection that was not found in the ceftazidime cohort, but these bacteria were sensitive to both levofloxacin and ceftazidime for two of the three patients (Table 4) . Increased rates of Pseudomonas infection or viridans group streptococcal bacteremia did not become apparent with levofloxacin prophylaxis, despite some concerns in the literature regarding these pathogens emerging with levofloxacin use (Pseudomonas) or quinolones in general (viridans streptococci) because of suboptimal minimal inhibitory concentrations. Our use of the higher dose of levofloxacin at 750 mg daily may have mitigated these susceptibility problems. Thus, we found no evidence in our study that levofloxacin prophylaxis led to adverse consequences as reflected by the emergence of antibiotic resistance or a change in the pattern of infections.
The RFS curves were indistinguishable during the period of neutropenia when the antibiotic activity is operative, showing no evidence of superiority for one prophylaxis regimen over the other. There was a trend toward better long-term RFS in the levofloxacin group (P ¼ 0.13), but this result must be interpreted with caution because the patients were treated with levofloxacin and ceftazidime in different time periods. Thus, improvements in overall care in the later time period may account for better survival in the levofloxacin group. On the other hand, an analysis of RFS by year of transplantation over the study period showed no such trend (data not shown).
There were some limitations to our study. First, this was not a randomized trial comparing two antibiotic prophylaxis regimens, but was rather a retrospective analysis of two cohorts from sequential time periods. Our goal was to assess the clinical and microbiological impact of adopting levofloxacin antibiotic prophylaxis for myeloablative allogeneic transplant at one HCT center that previously used a b-lactam antibiotic for prophylaxis. Definitive conclusions about the relative efficacy of these antibiotics would require a randomized controlled trial. We adjusted our models when appropriate for observed differences in gender and cell source between prophylaxis groups, but there may have been other factors related to changes in hospital practices over time for which we could not adjust. For example, the choice of antibiotic to be used for breakthrough fever on prophylaxis was left to the patient care teams, thus there were differences in antibiotic usage patterns within a prophylaxis group. Second, although levofloxacin resistance did not emerge as an important problem, ongoing use of an antibiotic in a community may alter the pathogens encountered on a longer time scale. Continued vigilance is necessary. Third, the study reflects the experience at a single transplant center, and may not be applicable to patients receiving non-myeloablative or autologous transplants. Fourth, there were various reasons that prophylactic antibiotics were ceased or changed, including persistent fever and drug toxicity, and this study did not focus on the reasons for antibiotic failure or the incidence of toxicity. Fifth, the difference in antibiotic costs was very conservative and was based on only drug acquisition costs. As levofloxacin is administered once daily (oral or i.v.), whereas ceftazidime is administered thrice a day i.v., the total administration costs of ceftazidime are likely to be substantially higher than those of levofloxacin. We did not calculate the administration costs of these medications because different institutions charge very different rates making the comparison less useful.
In conclusion, levofloxacin is an attractive antibiotic for prophylaxis in patients undergoing myeloablative allogeneic HCT and compared favorably with ceftazidime. The use of levofloxacin was associated with lower antibiotic acquisition costs and a reduction in significant bloodstream infections compared with ceftazidime. Levofloxacin-resistant bacteria were detected in patients receiving levofloxacin prophylaxis, but there was no significant increase in antibiotic-resistant bacteria. Although patients receiving levofloxacin prophylaxis had a higher rate of developing fever, these patients were usually switched to ceftazidime, thereby helping to preserve extended spectrum antibiotics, such as imipenem for those who fail to respond to empirical therapy. This strategy may help to further limit costs and the emergence of antibiotic resistance.
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